AU6745594A - Pharmacologically active CNS compounds - Google Patents
Pharmacologically active CNS compoundsInfo
- Publication number
- AU6745594A AU6745594A AU67455/94A AU6745594A AU6745594A AU 6745594 A AU6745594 A AU 6745594A AU 67455/94 A AU67455/94 A AU 67455/94A AU 6745594 A AU6745594 A AU 6745594A AU 6745594 A AU6745594 A AU 6745594A
- Authority
- AU
- Australia
- Prior art keywords
- hydrogen
- halo
- alkyl
- compounds
- pharmacologically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Liquid Crystal Substances (AREA)
- Paper (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a series of compounds of formula (I) <CHEM> and salts thereof, wherein for example, R<1> and R<2>, which may be the same or different each represent -NR<1><3>R<1><4> where R<1><3> and R<1><4> may each independently represent hydrogen or alkyl or, taken together with the nitrogen atom to which they are attached form a heterocyclic ring, optionally substituted by one or more alkyl or arylalkyl groups and optionally containing a further heteroatom; R<3> is hydrogen, haloalkyl, alkoxymethyl or alkyl; R<4> is hydrogen, nitro or halo; R<5> is hydrogen or halo; R<6> is hydrogen, halo, nitro, amino, alkylamino or dialkylamino; R<7> is hydrogen or halo; R<8> is hydrogen or halo; The compounds may be used for the treatment or prophylaxis of a neurodegenerative or other neurological disorder of the CNS, the aetiology or which includes excessive release of the neurotransmitter glutamate.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9012316 | 1990-06-01 | ||
GB909012316A GB9012316D0 (en) | 1990-06-01 | 1990-06-01 | Pharmacologically active cns compounds |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU78097/91A Division AU652753B2 (en) | 1990-06-01 | 1991-05-31 | 5-aryl pyrimidine, processes for its production and use as treatment for CNS disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
AU6745594A true AU6745594A (en) | 1994-09-15 |
AU680252B2 AU680252B2 (en) | 1997-07-24 |
Family
ID=10676964
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU78097/91A Ceased AU652753B2 (en) | 1990-06-01 | 1991-05-31 | 5-aryl pyrimidine, processes for its production and use as treatment for CNS disorders |
AU67455/94A Expired - Fee Related AU680252B2 (en) | 1990-06-01 | 1994-07-13 | Pharmacologically active CNS compounds |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU78097/91A Ceased AU652753B2 (en) | 1990-06-01 | 1991-05-31 | 5-aryl pyrimidine, processes for its production and use as treatment for CNS disorders |
Country Status (25)
Country | Link |
---|---|
EP (2) | EP0679645A1 (en) |
JP (1) | JPH06340634A (en) |
KR (1) | KR920000733A (en) |
AT (1) | ATE141263T1 (en) |
AU (2) | AU652753B2 (en) |
CA (1) | CA2043640A1 (en) |
CZ (1) | CZ281070B6 (en) |
DE (1) | DE69121317T2 (en) |
DK (1) | DK0459819T3 (en) |
ES (1) | ES2093078T3 (en) |
FI (1) | FI912623A (en) |
GB (1) | GB9012316D0 (en) |
GR (1) | GR3021237T3 (en) |
HU (2) | HUT58707A (en) |
IE (1) | IE911861A1 (en) |
IL (2) | IL113599A (en) |
MY (2) | MY136248A (en) |
NO (1) | NO180375C (en) |
NZ (3) | NZ248501A (en) |
PL (2) | PL166656B1 (en) |
PT (1) | PT97827B (en) |
RU (1) | RU2091374C1 (en) |
SK (1) | SK278444B6 (en) |
TW (1) | TW224460B (en) |
ZA (1) | ZA914165B (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI895821A0 (en) * | 1988-12-07 | 1989-12-05 | Wellcome Found | PHARMACEUTICAL ACTIVE CNS FOERENINGAR. |
US5629016A (en) * | 1991-01-30 | 1997-05-13 | Glaxo Wellcome Inc. | Water-dispersible tablets |
ATE133068T1 (en) * | 1991-01-30 | 1996-02-15 | Wellcome Found | WATER SOLUBLE TABLETS |
GB9215908D0 (en) * | 1992-07-27 | 1992-09-09 | Wellcome Found | Water dispersible tablets |
GB9226377D0 (en) * | 1992-12-18 | 1993-02-10 | Babbedge Rachel C | Pharmaceutical compositions |
WO1994014780A1 (en) * | 1992-12-18 | 1994-07-07 | The Wellcome Foundation Limited | Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors |
US5698226A (en) * | 1993-07-13 | 1997-12-16 | Glaxo Wellcome Inc. | Water-dispersible tablets |
GB9319341D0 (en) * | 1993-09-17 | 1993-11-03 | Wellcome Found | Novel process |
FR2741879A1 (en) * | 1995-12-05 | 1997-06-06 | Esteve Labor Dr | FLUOROPHENYL-TRIAZINE AND PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS |
US6440965B1 (en) * | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
GB9726987D0 (en) | 1997-12-22 | 1998-02-18 | Glaxo Group Ltd | Compounds |
US6583148B1 (en) | 1999-04-08 | 2003-06-24 | Krenitsky Pharmaceuticals, Inc. | Neurotrophic substituted pyrimidines |
DE19918325A1 (en) | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Extruded drug dosage form, e.g. granulate for tableting, comprising an active agent in a polysaccharide-containing matrix, giving a release profile which is controllable by extrusion conditions and/or the inclusion of additives |
BRPI0014526C1 (en) | 1999-09-16 | 2021-05-25 | Mitsubishi Tanabe Pharma Corp | cyclic compounds of six elements containing aromatic nitrogen, pharmaceutical composition and use thereof |
US7273868B2 (en) | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
MXPA02010693A (en) | 2000-04-28 | 2003-03-10 | Tanabe Seiyaku Co | Cyclic compounds. |
US7205297B2 (en) | 2000-07-24 | 2007-04-17 | Krenitsky Pharmaceuticals, Inc. | Substituted 5-alkynyl pyrimidines having neurotrophic activity |
NZ527741A (en) | 2001-02-26 | 2005-02-25 | Tanabe Seiyaku Co | Pyridopyrimidine or naphthyridine derivative |
IL162859A0 (en) * | 2002-02-05 | 2005-11-20 | Novo Nordisk As | Novel aryl-and heteroarylpiperazines |
TW200637556A (en) * | 2005-01-31 | 2006-11-01 | Basf Ag | Substituted 5-phenyl pyrimidines I in therapy |
AU2006264966B2 (en) | 2005-07-04 | 2013-02-21 | High Point Pharmaceuticals, Llc | Histamine H3 receptor antagonists |
EP2038256A1 (en) | 2006-05-23 | 2009-03-25 | TransTech Pharma, Inc | 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ']-bipyridine and its use as a medicament |
CA2659570C (en) | 2006-05-29 | 2015-10-06 | High Point Pharmaceuticals, Llc | 3-(1,3-benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)-pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist |
EP2014656A3 (en) | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | New heteocyclic h3 antagonists |
JP2014517016A (en) | 2011-06-10 | 2014-07-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pyrimidine having BTK inhibitory activity and composition of pyrimidine compound and method for producing the same |
JO3517B1 (en) | 2014-01-17 | 2020-07-05 | Novartis Ag | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 |
US10093646B2 (en) | 2014-01-17 | 2018-10-09 | Novartis Ag | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 |
EA036446B1 (en) | 2016-06-14 | 2020-11-11 | Новартис Аг | Compounds and compositions for inhibiting the activity of shp2 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE518622A (en) * | ||||
FI895821A0 (en) * | 1988-12-07 | 1989-12-05 | Wellcome Found | PHARMACEUTICAL ACTIVE CNS FOERENINGAR. |
US5136080A (en) * | 1989-12-04 | 1992-08-04 | Burroughs Wellcome Co. | Nitrile compounds |
-
1990
- 1990-06-01 GB GB909012316A patent/GB9012316D0/en active Pending
-
1991
- 1991-05-30 ZA ZA914165A patent/ZA914165B/en unknown
- 1991-05-31 MY MYPI95001459A patent/MY136248A/en unknown
- 1991-05-31 AT AT91304935T patent/ATE141263T1/en not_active IP Right Cessation
- 1991-05-31 IE IE186191A patent/IE911861A1/en unknown
- 1991-05-31 HU HU911826A patent/HUT58707A/en unknown
- 1991-05-31 IL IL113599A patent/IL113599A/en not_active IP Right Cessation
- 1991-05-31 RU SU914895583A patent/RU2091374C1/en active
- 1991-05-31 JP JP3235334A patent/JPH06340634A/en active Pending
- 1991-05-31 CZ CS911643A patent/CZ281070B6/en unknown
- 1991-05-31 CA CA002043640A patent/CA2043640A1/en not_active Abandoned
- 1991-05-31 KR KR1019910009010A patent/KR920000733A/en not_active Application Discontinuation
- 1991-05-31 NO NO912100A patent/NO180375C/en unknown
- 1991-05-31 PL PL91290496A patent/PL166656B1/en unknown
- 1991-05-31 NZ NZ248501A patent/NZ248501A/en unknown
- 1991-05-31 IL IL9833091A patent/IL98330A/en active IP Right Grant
- 1991-05-31 EP EP95111314A patent/EP0679645A1/en not_active Withdrawn
- 1991-05-31 MY MYPI91000962A patent/MY109958A/en unknown
- 1991-05-31 NZ NZ238360A patent/NZ238360A/en unknown
- 1991-05-31 TW TW080104285A patent/TW224460B/zh active
- 1991-05-31 PL PL91305331A patent/PL170373B1/en unknown
- 1991-05-31 SK SK1643-91A patent/SK278444B6/en unknown
- 1991-05-31 NZ NZ272001A patent/NZ272001A/en unknown
- 1991-05-31 PT PT97827A patent/PT97827B/en not_active IP Right Cessation
- 1991-05-31 EP EP91304935A patent/EP0459819B1/en not_active Expired - Lifetime
- 1991-05-31 DE DE69121317T patent/DE69121317T2/en not_active Expired - Fee Related
- 1991-05-31 DK DK91304935.9T patent/DK0459819T3/en active
- 1991-05-31 ES ES91304935T patent/ES2093078T3/en not_active Expired - Lifetime
- 1991-05-31 AU AU78097/91A patent/AU652753B2/en not_active Ceased
- 1991-05-31 FI FI912623A patent/FI912623A/en not_active Application Discontinuation
-
1994
- 1994-07-13 AU AU67455/94A patent/AU680252B2/en not_active Expired - Fee Related
-
1995
- 1995-06-30 HU HU95P/P00669P patent/HU211649A9/en unknown
-
1996
- 1996-10-03 GR GR960402585T patent/GR3021237T3/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU6745594A (en) | Pharmacologically active CNS compounds | |
HU896723D0 (en) | Process for preparation of guanidine-derivatives and insecticid compositions comprising these compounds as active ingredient | |
PH25859A (en) | Composition for treatment of ischemic disorder | |
HUT54667A (en) | Process for producing alkyl-substituted piperazine derivatives and pharmaceutical compositions containing them | |
IE821434L (en) | Arylsulphonamides. | |
IL86462A0 (en) | Alkanesulfonanilide derivatives,processes for preparation thereof and pharmaceutical composition comprising the same | |
IE811580L (en) | Herbicidal compounds | |
AU1406888A (en) | Biologically active compounds | |
EP0726269A4 (en) | Quinolinecarboxylic acid derivative and salt thereof | |
HU9600597D0 (en) | 4-alkylthio-pyrimidin-5-yl acetic acid derivates and fungicidal compositions containing them as an active ingredient | |
BR8603928A (en) | HYDRAZINE-DIFENYLIC ETHERS COMPOUNDS, PROCESS FOR THEIR PREPARATION, HERBICIDE COMPOSITION AND PROCESS TO COMBAT THE GROWTH OF UNDESIRABLE PLANTS | |
NO954109L (en) | Analogous Process for Preparing Therapeutically Active Substituted 5-Arylpyrimidines | |
TH11828EX (en) | CNS-related compounds that have pharmacological effects |